XML 57 R42.htm IDEA: XBRL DOCUMENT v3.26.1
Equity Compensation Plans (Tables)
3 Months Ended
Mar. 31, 2026
Equity Compensation Plans [Abstract]  
Schedule of Total Stock Option Activity

The following table summarizes the Company’s total stock option activity for the three months ended March 31, 2026:

 

   Options
(in thousands)
   Weighted
Average
Exercise
Price
   Weighted
Average
Remaining
Contractual
Term in
Years
   Intrinsic
Value
(in thousands)
 
Options outstanding as of January 1, 2025   500   $6.82    1.3   $
 
Granted   
    
        
 
Exercised   
    
        
 
Forfeited   
    
        
 
Options outstanding as of March 31, 2026   500   $6.82    1.0   $
 
Schedule of Outstanding and Exercisable Stock Options

Outstanding and exercisable stock options as of March 31, 2026 are as follows:

 

    Options Outstanding  Options Exercisable
Exercise Prices   Number of
Options
Outstanding
(in thousands)
  Weighted
Average
Remaining Life
(Years)
   Number of
Options
Exercisable
(in thousands)
  Weighted
Average
Remaining Life
(Years)
   Intrinsic
Value
(in thousands)
 
$6.82   500   1.0   500   1.0   $
 
Schedule of Restricted Stock Unit Activity

The following table summarizes the Company’s restricted stock unit activity for the three months ended March 31, 2026:

 

   Number
Outstanding
(in thousands)
   Weighted
Average
Grant Date
Fair Value
 
Nonvested restricted stock units as of January 1, 2026   3,141   $1.25 
Granted   
    
 
Vested   (707)   1.39 
Forfeited   (928)   1.87 
Nonvested restricted stock units as of March 31, 2026   1,506   $0.80 
Schedule of Non-Cash Stock-Based Compensation Recognized in the Statement of Operations

The following table summarizes the aggregate non-cash stock-based compensation recognized in the statement of operations for stock awards, employee stock options and employee restricted stock units (in thousands):

 

   Three Months Ended
March 31,
 
   2026   2025 
Cost of revenues  $(16)  $103 
Marketing and sales   8    (176)
General and administrative   162    363 
Research and development   2    78 
Total non-cash stock-based compensation  $156   $368